IFP Advisors
LUCD icon

IFP Advisors’s Lucid Diagnostics LUCD Stock Holding History

IFP Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$39 Sell
52
-105
-67% -$98 ﹤0.01% 5084
2026
Q2 		$168 Buy
157
+120
+324% +$129 ﹤0.01% 4882
2026
Q1 		$43 Buy
37
+9
+32% +$11 ﹤0.01% 4848
2025
Q4 		$31 Sell
28
-355
-93% -$397 ﹤0.01% 4762
2025
Q3 		$387 Buy
+383
New +$418 ﹤0.01% 4249

Other funds holding LUCD

Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
TIA
Traphagen Investment Advisors Oradell, New Jersey $1.46B AUM 14.92% 1-Year Est. Return
Sax Wealth Advisors
Sax Wealth Advisors Parsippany, New Jersey $3.5B AUM 13.73% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

IFP Advisors's LUCD Position: Q3 2026 in Review

IFP Advisors reduced its Lucid Diagnostics (LUCD) stake by 67% in Q3 2026, selling an estimated $98 and leaving 52 shares worth $39. The position accounts for ﹤0.01% of the portfolio, ranked #5084.

IFP Advisors first reported a position in LUCD in Q3 2025 and has held it in 5 quarters since. The position peaked at $387 in Q3 2025. 10 funds tracked by Wall St. Rank hold LUCD as of Q3 2026.

  • IFP Advisors held 52 shares of Lucid Diagnostics worth $39 as of Q3 2026.
  • IFP Advisors sold 105 Lucid Diagnostics shares in Q3 2026, an estimated $98.
  • Lucid Diagnostics made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5084 holding.
  • IFP Advisors first reported a position in Lucid Diagnostics in Q3 2025 and has held it in 5 quarters since.
  • IFP Advisors's Lucid Diagnostics position peaked at $387 in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.